By Daniella Parra
Eterna Therapeutics Inc. (Nasdaq: ERNA), announced the successful completion of a private placement transaction, generating approximately $8.7 million.
The notes, bearing a 6.0% annual interest rate and maturing in July 2028, can be converted into Eterna common stock at $2.86 per share, the company said.
Each purchaser received warrants to purchase 200% of the number of shares of Eterna common stock. Eterna is a life science company committed to realizing the potential of mRNA cell engineering.